Introduction
In collaboration with physiologist W. M. Bayliss, English physician E. H. Starling discovered secretin in 1902.[1]During that era, hormonal control of pancreatic secretions conflicted with the teachings of the Pavlov school that only neural reflexes were involved in pancreas response to duodenal acidification.[2]The findings of Bayliss and Starling remain as a scientific truth, but healthcare professionals have abetter-developed understanding of secretin and its function.
Secretin is secreted by S cells in theduodenum and affects numerous other organ systems. Secretin receptors (SR) are expressed in the basolateral domain of several cell types.[3]Besidesregulating the growth of epithelial cells in the pancreas and biliary system, secretinadditionally exerts trophic effects.
Cellular Level
Initially, secretin begins as an amino acid precursor known as prosecretin until activation via gastric acid. Prosecretin contains an N-terminal peptide, spacer, secretin, and C-terminal peptide; while the N-terminal is a single peptide, secretin itself makes up residues 28 to 54, and the C-terminal peptide is 72-amino acids.[4]Secretin is a peptide hormone composed of 27 amino acids. The sequence is like that of a gastric inhibitory peptide (GIP), vasoactive intestinal peptide (VIP), and glucagon.
Secretinis produced in the duodenal mucosa and acts on the pancreas where it stimulates the release of bicarbonate and water. While this role in digestive physiology has been known, studiesrecently identified the mediating receptor function of secretin.[5]Along with the receptors of VIP and glucagon, the secretin receptor is part of the G-protein-coupled receptor superfamily. Pancreaticcentroacinarcells have secretin receptors in their plasma membrane. Once bound to the receptor, secretin stimulatesadenylatecyclase and converts ATP tocAMP.cAMPis a second messenger and causes the pancreas to secrete bicarbonate. The cAMP system plays a key role in the modulation of large biliary secretion since it is activated by secretin[6], as well as increased cholangiocyte proliferation.[7]
The mechanisms of secretin receptors signal termination involve phosphorylation[8], which are mediated by GPCR kinases[9]. The receptors are abundant on duct and acinar cells and moderate the release of secretin-stimulated fluid andbicarbonate secretion. Moreover,receptors are present in brain cells and neurons in the vagus nerve; secretin receptors are also found on tumors of the gastrointestinal (GI)tract.[10]
Function
Secretin has 3 main functions: regulation of gastric acid, regulation of pancreatic bicarbonate, and osmoregulation.
Regulation of Gastric Acid Secretion and Pancreatic Bicarbonate
The major physiological actions of secretin are stimulation of pancreatic fluid and bicarbonate secretion. S cells in the small intestine emit secretin. Gastric acid stimulates secretin release, allowing movementinto the duodenal lumen.Secretin causes an increase in pancreatic and biliary bicarbonate secretion and a decrease in gastric H+ secretion. Secretin stimulates the secretion of bicarbonate-rich pancreatic fluid.[11]Secretin enters the intestinal lumen and stimulates bicarbonate secretion, ultimately neutralizing gastric H+, which plays an essential role in fat digestion by creating a moreneutral (pH 6 to 8) environment. H+ and fatty acids in the duodenumregulate secretin release.
Secretin neutralizes the pH in the duodenum by optimizing the functionality of pancreatic amylase and pancreatic lipase. (1) Via the second messenger action of cAMP, bicarbonate release causes neutralization of the acidic environment, thus establishing a pH favorable for the action of digestive enzymes.[12]Secretin increases bicarbonate secretion from duodenal Brunner's gland as well; this mechanism buffers the acidity from chyme and reduces secretion of acid by parietal cells.
Osmoregulation
Water homeostasis is crucialin maintaining the balance between water intake and excretion in the body.
Osmoregulatory functions of secretin in the brain are similar to those of angiotensin II.[13]Secretin isfound in the magnocellular neurons of the paraventricular and supraoptic nuclei of the hypothalamus. In states of elevated osmolality, secretin is released from the posterior pituitary - this causes activation of vasopressin release in the hypothalamus. Vasopressin affects the collecting ducts, where it induces the insertion of aquaporin 2 water channels on the apical membranes of these cells.[14]Secretin has been shown to induce an increase in urinary volume.
Related Testing
Clinically, the main use of secretin is in the diagnosis of gastrin-secreting tumors, such as in Zollinger-Ellison syndrome. Under normal physiologic conditions, secretin inhibits gastrin release; however, in gastrinoma pathologies, the administration of secretin will cause an overall increase in gastrin release. This idea is the basis for the secretin stimulation test,which is usedto determinethe presence ofgastrin-producing tumors.[15]Proper technique of the secretin stimulation test placesa tube down the throat through the stomach, and into the duodenum. Once the tube is in place, administration of exogenous secretin occurs, and analyzation ofduodenalaspirations followappropriately.
Secretin plays a role in diagnosing pancreatic insufficiency. Administration of secretin increases pancreatic secretions and causes dilation of pancreatic ducts. Therefore, secretin administration occurs during endoscopic retrograde cholangiopancreatography (ERCP) to aid incannulization.[16]Recent studies show that secretin-enhanced ERCP is more efficaciousin the evaluationof pancreatic secretions, and possible ductal obstruction.[17]Ultimately, secretin-enhanced ERCP is more useful in detecting inflammatory and neoplastic conditions of the pancreas versus the use of conventional methods such as magnetic resonance imaging or computerized tomography.
Pathophysiology
Despite the primary action of secretin being the bicarbonate secretion and production of pancreatic fluid[18], it also functions as an enterogastrone. Released by ingested fats, an enterogastrone is a substance that inhibits gastric acid secretion. Secretin inhibits gastric acid secretion.[19]
Similar to other intestinal peptides, secretin displays satiety-inducing features when administered.[20]Centrally, the action is controlled by the melanocortin system; peripherally, secretin signals through the sensory fibers of the vagus nerve.[21]
Abnormalities in secretin release parallel abnormalities in underlying pathologies, such as Syndrome of inappropriate antidiuretic hormone (SIADH). Patients with SIADH have normal vasopressin function, but undergo translocation of aquaporin 2; therefore, without the release of secretin from the posterior pituitary, no vasopressin release would occur due to lack ofstimulationon the hypothalamus.
Clinical Significance
Cystic Fibrosis
Cystic fibrosis (CF) is a genetic disorder affecting multiple organs. CF is inheritedin an autosomal recessive manner. Mutationsin the cystic fibrosis transmembrane conductance regulator (CFTR) protein cause it.[22]When the CFTR is not functioning correctly, secretions become thick and viscous. The disorder is characterized by epithelial secretory dysfunction, ductal obstruction lesions, and defective chloride permeability in the pancreas. Normally, the pancreas secretes chloride, bicarbonate, and water in response to secretin; however, in cystic fibrosis, this response isgreatlydiminished, thuscausing dehydrated secretions and thickened mucus. Secretin-stimulated sonography and MRI can be used to diagnose exocrine pancreatic failure in cystic fibrosis.[23]
Autism and Pervasive Developmental Disorder
Recent studies hypothesize that secretin can be used totreat autism and pervasive developmental disorder (PDD). In a double-blind, placebo-controlled, crossover study, researchers gave asingle dose of IV porcine secretin to participants. The study resulted in improved language and behavior in children with these disorders and chronic diarrhea. Children with chronic, active diarrhea showed a reduction inabnormal behaviors when treated with secretin.[24]
Review Questions
References
- 1.
Henriksen JH, de Muckadell OB. Secretin, its discovery, and the introduction of the hormone concept. Scand J Clin Lab Invest. 2000 Oct;60(6):463-71. [PubMed: 11129062]
- 2.
Hirst BH. Secretin and the exposition of hormonal control. J Physiol. 2004 Oct 15;560(Pt 2):339. [PMC free article: PMC1665254] [PubMed: 15308687]
- 3.
Afroze S, Meng F, Jensen K, McDaniel K, Rahal K, Onori P, Gaudio E, Alpini G, Glaser SS. The physiological roles of secretin and its receptor. Ann Transl Med. 2013 Oct;1(3):29. [PMC free article: PMC4200670] [PubMed: 25332973]
- 4.
Kopin AS, Wheeler MB, Leiter AB. Secretin: structure of the precursor and tissue distribution of the mRNA. Proc Natl Acad Sci U S A. 1990 Mar;87(6):2299-303. [PMC free article: PMC53674] [PubMed: 2315322]
- 5.
Chow BK. Molecular cloning and functional characterization of a human secretin receptor. Biochem Biophys Res Commun. 1995 Jul 06;212(1):204-11. [PubMed: 7612008]
- 6.
Alpini G, Glaser S, Robertson W, Rodgers RE, Phinizy JL, Lasater J, LeSage GD. Large but not small intrahepatic bile ducts are involved in secretin-regulated ductal bile secretion. Am J Physiol. 1997 May;272(5 Pt 1):G1064-74. [PubMed: 9176215]
- 7.
Glaser S, Lam IP, Franchitto A, Gaudio E, Onori P, Chow BK, Wise C, Kopriva S, Venter J, White M, Ueno Y, Dostal D, Carpino G, Mancinelli R, Butler W, Chiasson V, DeMorrow S, Francis H, Alpini G. Knockout of secretin receptor reduces large cholangiocyte hyperplasia in mice with extrahepatic cholestasis induced by bile duct ligation. Hepatology. 2010 Jul;52(1):204-14. [PMC free article: PMC3049759] [PubMed: 20578263]
- 8.
Ozcelebi F, Holtmann MH, Rentsch RU, Rao R, Miller LJ. Agonist-stimulated phosphorylation of the carboxyl-terminal tail of the secretin receptor. Mol Pharmacol. 1995 Nov;48(5):818-24. [PubMed: 7476911]
- 9.
Shetzline MA, Premont RT, Walker JK, Vigna SR, Caron MG. A role for receptor kinases in the regulation of class II G protein-coupled receptors. Phosphorylation and desensitization of the secretin receptor. J Biol Chem. 1998 Mar 20;273(12):6756-62. [PubMed: 9506976]
- 10.
Körner M, Miller LJ. Alternative splicing of pre-mRNA in cancer: focus on G protein-coupled peptide hormone receptors. Am J Pathol. 2009 Aug;175(2):461-72. [PMC free article: PMC2716947] [PubMed: 19574427]
- 11.
CHRISTODOULOPOULOS JB, JACOBS WH, KLOTZ AP. Action of secretin on pancreatic secretion. Am J Physiol. 1961 Dec;201:1020-4. [PubMed: 13879310]
- 12.
Osnes M, Hanssen LE, Flaten O, Myren J. Exocrine pancreatic secretion and immunoreactive secretin (IRS) release after intraduodenal instillation of bile in man. Gut. 1978 Mar;19(3):180-4. [PMC free article: PMC1411891] [PubMed: 631638]
- 13.
Lee VH, Lee LT, Chu JY, Lam IP, Siu FK, Vaudry H, Chow BK. An indispensable role of secretin in mediating the osmoregulatory functions of angiotensin II. FASEB J. 2010 Dec;24(12):5024-32. [PMC free article: PMC2992369] [PubMed: 20739612]
- 14.
Nielsen S, DiGiovanni SR, Christensen EI, Knepper MA, Harris HW. Cellular and subcellular immunolocalization of vasopressin-regulated water channel in rat kidney. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11663-7. [PMC free article: PMC48044] [PubMed: 8265605]
- 15.
Brady CE. Secretin provocation test in the diagnosis of Zollinger-Ellison syndrome. Am J Gastroenterol. 1991 Feb;86(2):129-34. [PubMed: 1992623]
- 16.
Catalano MF, Lahoti S, Geenen JE, Hogan WJ. Prospective evaluation of endoscopic ultrasonography, endoscopic retrograde pancreatography, and secretin test in the diagnosis of chronic pancreatitis. Gastrointest Endosc. 1998 Jul;48(1):11-7. [PubMed: 9684658]
- 17.
Khalid A, Peterson M, Slivka A. Secretin-stimulated magnetic resonance pancreaticogram to assess pancreatic duct outflow obstruction in evaluation of idiopathic acute recurrent pancreatitis: a pilot study. Dig Dis Sci. 2003 Aug;48(8):1475-81. [PubMed: 12924639]
- 18.
You CH, Rominger JM, Chey WY. Effects of atropine on the action and release of secretin in humans. Am J Physiol. 1982 Jun;242(6):G608-11. [PubMed: 7091334]
- 19.
You CH, Chey WY. Secretin is an enterogastrone in humans. Dig Dis Sci. 1987 May;32(5):466-71. [PubMed: 2952476]
- 20.
Cheng CY, Chu JY, Chow BK. Central and peripheral administration of secretin inhibits food intake in mice through the activation of the melanocortin system. Neuropsychopharmacology. 2011 Jan;36(2):459-71. [PMC free article: PMC3055665] [PubMed: 20927047]
- 21.
Chu JY, Cheng CY, Sekar R, Chow BK. Vagal afferent mediates the anorectic effect of peripheral secretin. PLoS One. 2013;8(5):e64859. [PMC free article: PMC3667839] [PubMed: 23738005]
- 22.
O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet. 2009 May 30;373(9678):1891-904. [PubMed: 19403164]
- 23.
Engjom T, Tjora E, Wathle G, Erchinger F, Lærum BN, Gilja OH, Haldorsen IS, Dimcevski G. Secretin-stimulated ultrasound estimation of pancreatic secretion in cystic fibrosis validated by magnetic resonance imaging. Eur Radiol. 2018 Apr;28(4):1495-1503. [PMC free article: PMC5834563] [PubMed: 29134356]
- 24.
Kern JK, Van Miller S, Evans PA, Trivedi MH. Efficacy of porcine secretin in children with autism and pervasive developmental disorder. J Autism Dev Disord. 2002 Jun;32(3):153-60. [PubMed: 12108616]
Disclosure: Nicholas DiGregorio declares no relevant financial relationships with ineligible companies.
Disclosure: Sandeep Sharma declares no relevant financial relationships with ineligible companies.
